As a long-acting GLP-1 analog, Trulicity is bound to albumin, giving it an extended half-life of approximately 5 days that maintains steady-state insulin secretion throughout the week
In 2013 the two scientists reported that they had managed to create a drug candidate able to simultaneously target GLP-1 and GIP which they had found to effectively reverse obesity and insulin resistance in rodents, monkeys and humans
While side effects are often cited as a reason for GLP-1 non-adherence, the gap in persistence for the same molecule reflects deeper behavioral and systemic challenges
Although some pharmacies may have workarounds, they are currently facing legal challenges
Peptide degradation is real, measurable, and irreversible
Not everybody responds at the same rate